Taisho Pharmaceutical Holdings Co Ltd represents a strong commitment to providing quality healthcare products and improving the well-being of individuals. Their corporate philosophy revolves around innovation, ethical practices, and customer satisfaction. With a focus on research and development, Taisho Pharmaceutical aims to create cutting-edge solutions that address various health concerns. The company's values include integrity, respect for diversity, and a dedication to social responsibility. By combining their expertise with a customer-centered approach, Taisho Pharmaceutical strives to make a positive impact on society through their pharmaceutical and healthcare offerings.

Taisho Pharmaceutical Holdings Co Ltd is primarily present in Japan.

Taisho Pharmaceutical Holdings Co Ltd has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Bristol-Myers Squibb's OTC drug business in 2009, expanding its product portfolio and market presence. In 2011, Taisho successfully launched its flagship product, Lipovitan D, a popular energy drink that quickly gained popularity in the Japanese market. Additionally, the company has consistently focused on research and development, leading to the introduction of innovative pharmaceutical products. Taisho Pharmaceutical Holdings Co Ltd continues to foster strategic partnerships and expand its global presence, making it a leading player in the healthcare industry.

Taisho Pharmaceutical Holdings Co Ltd is a renowned pharmaceutical company with a rich history and notable background. Established in 1912, the company has been dedicated to improving healthcare and enhancing the well-being of individuals worldwide. With its headquarters in Tokyo, Japan, Taisho Pharmaceutical Holdings has expanded its operations to various countries, including the United States, China, and Southeast Asia. The company specializes in the research, development, manufacturing, and sales of a wide range of pharmaceutical products, including prescription drugs, OTC medications, and health-related products. Taisho Pharmaceutical Holdings Co Ltd has continuously strived for innovation and excellence, earning a reputation as a leading player in the global pharmaceutical industry.

The main competitors of Taisho Pharmaceutical Holdings Co Ltd in the market are Takeda Pharmaceutical Company Limited, Pfizer Inc., and GlaxoSmithKline plc.

Taisho Pharmaceutical Holdings Co Ltd is primarily active in the pharmaceutical industry.

The business model of Taisho Pharmaceutical Holdings Co Ltd revolves around the development, manufacture, and sale of pharmaceutical products. As a leading Japanese pharmaceutical company, Taisho focuses on research and innovation to provide high-quality medications to improve people's health and well-being. The company specializes in therapeutic areas such as internal medicine, dermatology, and nutraceuticals. Taisho Pharmaceutical Holdings Co Ltd strives to establish a strong presence in both domestic and international markets, ensuring accessibility to their diverse range of healthcare products. With a dedication to advancing medical solutions, Taisho remains committed to addressing society's healthcare needs effectively.

مُعامل القيمة السوقية إلى الأرباح لـ Taisho Pharmaceutical Holdings Co هو ٥٨٫٨٥.

مُعامِل القيمة إلى المبيعات Taisho Pharmaceutical Holdings Co هو ٢٫١٧.

نقاط جودة AlleAktien لـ Taisho Pharmaceutical Holdings Co هي 2/10.

المتوقعة Taisho Pharmaceutical Holdings Co الإيرادات هي ٣٢٤٫٩٧ مليارات JPY.

صافي الربح المتوقعة Taisho Pharmaceutical Holdings Co هو ١١٫٩٧ مليارات JPY.

Taisho Pharmaceutical Holdings Co Ltd is a Japanese company active in the pharmaceutical, healthcare, and cosmetics sectors. The company was established in 1912 and has its headquarters in Tokyo, Japan. The business model of Taisho Pharmaceutical focuses on the development, production, and sale of innovative products aimed at improving people's health and well-being. The company operates three main business fields: pharmaceuticals, healthcare, and cosmetics. In the pharmaceutical business, Taisho Pharmaceutical manufactures and distributes medications used to treat diseases and ailments. The company has a wide range of medications for cardiovascular diseases, diabetes, pain and inflammation, as well as viral and bacterial infections. The company utilizes advanced technologies and places a major emphasis on research and development to consistently bring the best medication to the market. The healthcare business of Taisho Pharmaceutical includes a range of products aimed at maintaining people's health and well-being. The company offers dietary supplements, vitamins, sports and fitness products, as well as health monitoring devices. These products are sold through various distribution channels such as pharmacies, drugstores, and online shops. In the cosmetics field, Taisho Pharmaceutical offers a wide range of products including skincare, haircare, and makeup products. The company has developed its cosmetics products using its pharmaceutical technologies and research to create the best products. These products are sold both in the Japanese market and internationally. In conclusion, Taisho Pharmaceutical's business model is focused on innovation, research, and development. The company aims to improve people's health and well-being by developing innovative products that cater to customer needs. With its diverse range of products and services, Taisho Pharmaceutical successfully operates in the pharmaceutical, healthcare, and cosmetics industries and will continue to serve customers worldwide in the future.

يوزع Taisho Pharmaceutical Holdings Co أرباحًا قدرها ١٠٠٫٠٠ JPY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Taisho Pharmaceutical Holdings Co في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـTaisho Pharmaceutical Holdings Co هو JP3442850008.

رمز WKN لـ Taisho Pharmaceutical Holdings Co هو A1JKG0.

الرمز المُختصر لـ Taisho Pharmaceutical Holdings Co هو 4581.T.

خلال آخر 12 شهراً، دفعت Taisho Pharmaceutical Holdings Co توزيعات أرباح بقيمة ١٠٠٫٠٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ١٫١٧ %. ومن المتوقع أن تدفع Taisho Pharmaceutical Holdings Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ١٠٠٫٧٢ JPY.

نسبة توزيعات الأرباح الحالية لـ Taisho Pharmaceutical Holdings Co هي ١٫١٧ %.

Taisho Pharmaceutical Holdings Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر أكتوبر, أبريل, أكتوبر, أبريل.

Taisho Pharmaceutical Holdings Co دفعت توزيعات الأرباح كل عام خلال الـ16 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ١٠٠٫٧٢ JPY. وهذا يعادل عائد توزيعات أرباح قدره ١٫١٧ %.

Taisho Pharmaceutical Holdings Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٥٠ JPY من Taisho Pharmaceutical Holdings Co المُعلن عنها في ١‏/٦‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٨‏/٣‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/٦‏/٢٠٢٤.

في العام 2023، وزعت Taisho Pharmaceutical Holdings Co ١٠٠ JPY كأرباح أسهم.

يتم توزيع أرباح Taisho Pharmaceutical Holdings Co بالعملة JPY.